Abstract: A targeted approach toward the treatment of TN breast cancer by using AMPI-109 is disclosed. AMPI-109 is a compound with remarkable “cancer-specific” characteristics. In particular, AMPI-109 demonstrates a striking targeted capability to inhibit the proliferation of TN breast cancer cells and to induce apoptosis in TN breast cancer cells. The growth inhibitory effect of AMPI-109 is independent of VDR. AMPI-109 can also be coupled with other oncolytic agents in treating a patient with TN breast cancer.
Type:
Grant
Filed:
January 17, 2014
Date of Patent:
January 10, 2017
Assignees:
The Regents of the University of Colorado, a body corporate, Trustees of Boston University
Inventors:
Hamid Gari, Jim Lambert, Scott Lucia, Rahul Ray, Ann Thor
Abstract: Provided are injectable, hyaluronic acid-based dermal filler compositions including conjugated vitamin C derivatives. The compositions provide for extended release of active vitamin C into tissue, promoting collagenesis and other benefits to skin.
Type:
Grant
Filed:
August 23, 2012
Date of Patent:
July 19, 2016
Assignee:
Allergan, Inc.
Inventors:
Futian Liu, Xiaojie Yu, Jessamine P. Winer-Jones, Nicholas J. Manesis, Hengli Liu, Gabriel Njikang
Abstract: Cells incorporating a synthetic molecule construct of the structure F—S1-S2-L where: F—S1 is an aminoalkylglycoside where F is a mono-, di-, tri- or oligo-saccharide and S1 is 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, or 5-aminopentyl; S2 is —CO(CH2)2CO—, —CO(CH2)3CO—, —CO(CH2)4CO— or —CO(CH2)5CO—; and L is phosphatidylethanolamine.
Type:
Grant
Filed:
December 17, 2013
Date of Patent:
May 31, 2016
Assignee:
KODE BIOTECH LIMITED
Inventors:
Nicolai Bovin, Lissa Gilliver, Stephen Henry, Elena Korchagina
Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
Abstract: The present invention relates to methods of treating a mycobacterial infection. In particular, this invention relates to methods, uses and compounds for use in treating mycobacterial infections, including tuberculosis. For example, the compounds may be an avermectin or a milbemycin. The avermectin or milbemycin may be selected from, but not limited to, one or more of ivermectin, moxidectin or selamectin. Exemplary microbial infections that may be treated include, but are not limited to, infections caused by Mycobacterium tuberculosis, Mycobacterium bovis, other mycobacteria of the tuberculosis complex, and non-tuberculous mycobacteria, including Mycobacterium ulcerans.
Type:
Grant
Filed:
April 16, 2014
Date of Patent:
April 12, 2016
Inventors:
Charles J. Thompson, Santiago Ramon-Garcia, Leah Elizabeth Lim
Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
Type:
Grant
Filed:
May 21, 2013
Date of Patent:
March 29, 2016
Assignees:
Idenix Pharmaceuticals, Inc., Centre National De La Recherche Scientifique, Universite Montpellier 2 Sciences Et Techniques
Inventors:
Christophe Claude Parsy, Francois-Rene Alexandre, Cyril B. Dousson, David Dukhan, Gilles Gosselin, Houcine Rahali, Dominique Surleraux
Abstract: The embodiments herein provide a method for isolation and purification of a novel oligosaccharide molecule from the fruits of Rosa arvensis for the treatment of diabetes. The fruit is dried, powdered and subjected to deionized water. The deionized water solution is subjected to silica gel column and the filtrate is subjected to ethanol-water mixture. The filtrate is subjected to column chromatography. The purified extract is structurally and chemically analyzed to find that the molecule is oligosaccharide. The purified oligosaccharide is administered to diabetic patients for 21 days. After the administration of oligosaccharide for 21 days the pancreatic tissues are collected and the blood glucose level in fasting and non fasting states is measured to find that there is significant effect in the blood glucose levels and the pancreatic tissue/cell regeneration after administration of the isolated oligosaccharide. The toxicity tests reveal that the oligosaccharide is non-toxic in nature.
Abstract: The present invention provides a novel sialo-sugar chain, a process for producing the sialo-sugar chain, and a device for producing the sialo-sugar chain. A sialo-sugar chain can be easily and efficiently mass-produced by reacting a sugar wherein a hydroxy groups is substituted with an alkynyl group (herein sometimes referred to as “alkynylated sugar”) with a specific sialic acid donor in the presence of a sialic acid-introducing enzyme.
Abstract: Novel pharmacological treatment of bacterial infectious diseases in humans by use of apramycin of formula (I) or apramycin derivatives having significantly low toxicity.
Abstract: The present invention provides a method for treating Lyme disease and/or a Borrelia infection in animals comprising administering to an animal in need thereof a therapeutically effective amount of cefovecin.
Type:
Grant
Filed:
December 20, 2012
Date of Patent:
February 23, 2016
Assignee:
Zoetis Services LLC
Inventors:
Patrick F. M. Meeus, Christopher L. Haber
Abstract: Biologically compatible polymers carry an imide and can be used as an adhesive, a hydrogel or both. A second biologically compatible polymer reactive with the imidated polymer can be used therewith to seal openings.
Type:
Grant
Filed:
December 17, 2014
Date of Patent:
February 16, 2016
Assignee:
The Johns Hopkins University
Inventors:
Jennifer H. Elisseeff, Iossif A. Strehin
Abstract: The present invention is directed to methods for preparing sorbose from glucose, said method comprising: (a) contacting the glucose with a silica-containing structure comprising a zeolite having a topology of a 12 membered-ring or larger, an ordered mesoporous silica material, or an amorphous silica, said structure containing Lewis acidic Ti4+ or Zr4+ or both Ti4+ and Zr4+ framework centers, said contacting conducted under reaction conditions sufficient to isomerize the glucose to sorbose. The sorbose may be (b) separated or isolated; or (c) converted to ascorbic acid.
Abstract: A process for the crystallization of a water-soluble compound from a solution of water and a solvent is provided. A process for the manufacture of crystalline sucrose from sugar palm juice or sucrose-containing biomass comprising such crystallization process is also disclosed.
Type:
Grant
Filed:
March 19, 2012
Date of Patent:
February 9, 2016
Assignee:
Wageningen Universiteit
Inventors:
Johan Pieter Marinus Sanders, Marieke Elisabeth Bruins, Jeroen Johannes Cornelis Franciscus Van Bon
Abstract: Methods of extracting chitin and chitosan from fungal biomass using a solution of one or more ammonia compounds, amines, and/or alkaline silicate compounds. The solution dissolves and extracts amino acids, fatty acids and other carbohydrates from the fungal cells leaving chitin and/or chitosan, and the extractant may be recovered from the liquid by simple phase changes such as heating or cooling, dissociation into volatile components, distillation and/or solidification and separation of immiscible extractants. Further lipid removal may be achieved with one or more organic solvents, which may also be recovered by distillation.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
February 2, 2016
Inventors:
Johannes Van Leeuwen, Glenn A. Norton, Sipho C. Ndlela, Daniel Rudnick
Abstract: The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising said glycosaminoglycan association.
Abstract: An embodiment of the present disclosure provides a composition that comprises hyaluronic acid, or its salt or derivative thereof, and an antimicrobial agent, such as zinc citrate, that does not degrade the hyaluronic acid molecule.
Abstract: A method for generating human milk oligosaccharides (HMOs) or precursors thereof, compounds obtainable by the method, and uses and compositions involving such compounds. The method comprising the steps of a) providing at least one donor selected from the group of compounds of any of formulae 5 to 10, b) providing at least one acceptor from a group of lactose, LNT, LNnT and derivatives thereof, c) providing at least one enzyme comprising a transglycosidase activity and/or a glycosynthase activity, d) preparing a mixture of the at least one donor, at least one acceptor and at least one enzyme provided in steps a), b) and c); and e) incubating the mixture prepared according to step d).
Type:
Grant
Filed:
May 14, 2012
Date of Patent:
January 12, 2016
Assignee:
GLYCOM A/S
Inventors:
Gyula Dekany, Elise Champion, Andreas Schroven, Markus Hederos
Abstract: An object of the present invention is to provide an agent for suppressing elevation of blood alcohol concentration and a method for suppressing elevation of blood alcohol concentration, the agent and the method enabling prevention of an intoxication state upon drinking and further prevention of hepatic dysfunctions due to drinking such as fatty liver. Provided are an agent for suppressing elevation of blood alcohol concentration, comprising a dextrin as an active ingredient, and a method for suppressing elevation of blood alcohol concentration, comprising, when alcohol is ingested, ingesting 0.5 parts by mass or more of a digestible dextrin and/or an indigestible dextrin relative to 1 part by mass of the ingested alcohol.
Abstract: The invention relates to selected carbohydrate-lipid constructs and their use as mimics of ligands for receptors expressed by virus. In particular, the invention relates to the use of selected carbohydrate-lipid constructs in methods of inhibiting virus infection and/or promoting clearance of virus from infected subjects. Carbohydrate-lipid constructs selected for use in these methods where the virus is Human Immunodeficiency Virus (HIV) are provided.